243 related articles for article (PubMed ID: 17959432)
1. A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans.
Seng KY; Vicini P; Nestorov IA
Conf Proc IEEE Eng Med Biol Soc; 2006; Suppl():6485-8. PubMed ID: 17959432
[TBL] [Abstract][Full Text] [Related]
2. A fuzzy physiologically based pharmacokinetic modeling framework to predict drug disposition in humans.
Seng KY; Vicini P; Nestorov IA
Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():5037-40. PubMed ID: 17947127
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic modeling of drug disposition in rat and human: a fuzzy arithmetic approach.
Seng KY; Nestorov I; Vicini P
Pharm Res; 2008 Aug; 25(8):1771-81. PubMed ID: 18363078
[TBL] [Abstract][Full Text] [Related]
4. Simulating pharmacokinetic and pharmacodynamic fuzzy-parameterized models: a comparison of numerical methods.
Seng KY; Nestorov I; Vicini P
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):595-621. PubMed ID: 17710517
[TBL] [Abstract][Full Text] [Related]
5. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
6. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
7. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetics (PBPK).
Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
[TBL] [Abstract][Full Text] [Related]
9. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
Poulin P
J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
11. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
[TBL] [Abstract][Full Text] [Related]
12. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
13. Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling.
Meyer M; Schneckener S; Ludewig B; Kuepfer L; Lippert J
Drug Metab Dispos; 2012 May; 40(5):892-901. PubMed ID: 22293118
[TBL] [Abstract][Full Text] [Related]
14. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
15. Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam.
Gueorguieva II; Nestorov IA; Rowland M
J Pharmacokinet Pharmacodyn; 2004 Jun; 31(3):185-213. PubMed ID: 15518244
[TBL] [Abstract][Full Text] [Related]
16. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
17. Fuzzy least squares for identification of individual pharmacokinetic parameters.
Seng KY; Nestorov I; Vicini P
IEEE Trans Biomed Eng; 2009 Dec; 56(12):2796-805. PubMed ID: 19695981
[TBL] [Abstract][Full Text] [Related]
18. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.
Jones HM; Barton HA; Lai Y; Bi YA; Kimoto E; Kempshall S; Tate SC; El-Kattan A; Houston JB; Galetin A; Fenner KS
Drug Metab Dispos; 2012 May; 40(5):1007-17. PubMed ID: 22344703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
